09/05/2019 20:29:27

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

NEW YORK, May 09, 2019 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On January 25, 2019, Southern Investigative Reporting Foundation (“SIRF”) published a report alleging that Corcept paid doctors to prescribe its drug Korlym for off-label uses. 

Following publication of the SIRF report, Corcept’s stock price fell $1.52 per share, or more than 11%, to close at $12.29 per share on January 25, 2019. 

On January 31, 2019, Corcept forecast a sharp slowdown in sales of Korlym, projecting full-year 2019 revenue of $285 million to $315 million, significantly lower than investor and analyst expectations of $328 million. 

On this news, Corcept’s stock price fell $1.15 per share, or more than 10%, to close at $10.03 per share on February 1, 2019. 

On February 5, 2019, Blue Orca Capital published a report alleging that Corcept’s “sole specialty pharmacy and exclusive distributor is an undisclosed related party” and that the relationship “creates a material risk that the Company is using its captured pharmacy to boost sales, hide losses, or engage in other financial shenanigans.” 

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:

Robert S. Willoughby

Pomerantz LLP

rswilloughby@pomlaw.com

Related content
28 May - 
Corcept Therapeutics to Present Data from Phase 1/2 Tri..
17 May - 
Bragar Eagel & Squire, P.C. Reminds Investors That Clas..
13 May - 
CRBP, NIO & CORT Deadline Alert - Bronstein, Gewirtz & ..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Regulatory news

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Annual Financial Report and Notice of Annual General Meeting
2
What to Make of the ‘Quantum Advantage’ at SEMICON West?
3
China Gold International Reports Results of its Annual General and Special Meeting of Shareholders
4
Cambium Networks Corporation Announces Pricing of Initial Public Offering
5
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Zuora, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Related stock quotes


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
26 June 2019 06:09:02
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB6 - 2019-06-26 07:09:02 - 2019-06-26 06:09:02 - 1000 - Website: OKAY